How Can Genomic Profiling Benefit Breast Cancer Patients?

Published on

Topics include: Understanding

Access to genomic profiling is quite limited, specially in Europe. But profiling the tumor of a patient might provide them with more therapeutic options. Dr. Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in breast cancer, explains why genomic profiling can be beneficial to patients. 

This interview was recorded at the European Society of Medical Oncology (ESMO) congress held in Madrid (September 2017). Lung cancer videos recorded at ESMO 17 are part of an educational program by the Patient Empowerment Foundation (PEF). We thank Roche for their support.

View more programs featuring

Related Programs

PARP Inhibitors In BRCA-Mutated Breast Cancer

PARP inhibitors are effective for BRCA-mutated ovarian cancer patients, but how do they stack up against BRCA-mutated breast cancer? Dr. Giuseppe Curigliano highlights recent study results.


What Are the Main Subtypes of Breast Cancer?

What are the four subtypes of breast cancer? Dr. Giuseppe Curigliano explains the subtypes and which treatment is best for each type.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on September 25, 2017